ESMO Media Releases

More people with non-small cell lung cancer (NSCLC) are likely to benefit from new drugs that target molecular alterations in tumour cells, with less need for chemotherapy, following results of multiple landmark clinical trials reported for the first time in late-breaking presentations at the ESMO Congress 2023  

Artificial intelligence (AI) has made a grand entrance into the public debate this year, but researchers have long been investigating its potential to transform cancer care and improve patient outcomes

Under the promise to “Disseminating innovative research for optimal cancer care” as this year’s tagline reads, the ESMO Congress 2023 will be held in Madrid between 20-24 October 2023 with a virtual component to allow as many people as possible to attend.

The Molecular Analysis for Precision Oncology Congress 2023 (MAP) is the appointment where experts present the latest developments and discuss the present and future of the rapidly evolving field of precision oncology, whose aim is to identify genomic alterations to provide the best possible personalised treatment to patients with cancer. 

The new online tool comes in an interactive, concise, and updatable visual format to support practicing oncologists in the rapidly evolving medical field

The ESMO Breast Cancer Congress 2023, will be held onsite in Berlin, Germany, and online, through a virtual platform, between 11-13 May 2023

Adding immunotherapy to standard chemotherapy for first-line treatment of advanced or first recurrence of endometrial cancer significantly improves progression-free survival (PFS) compared to chemotherapy alone, with a promising early indication of improved overall survival (OS)

ESMO is pleased to announce a combination of brand-new and well-established events happening in March, tackling two specific areas of oncology, with leading experts discussing novel clinical data and the latest treatment options

A total of 1,261,990 people will die from cancer in 2023 in the EU (EU-27). A further 172,314 people will die from the disease in the UK, according to new research published in the leading cancer journal Annals of Oncology today 

The ESMO Targeted Anticancer Therapies Congress 2023, the gathering focusing on promising new anticancer targets and agents, with a particular emphasis on those in early phase clinical development, will be held in Paris, France, on 6-8 March 2023.

The ESMO Gynaecological Cancers Congress 2023, the annual event dedicated to improving the practice of gynaecological cancers specialists worldwide, will provide an overview of the latest treatments as well as insights into the biology and biomarkers of ovarian, uterine, cervical and even rare gynaecological cancers.

The European Society for Medical Oncology (ESMO) has developed a quality of life (QoL) checklist that is now integral to the ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) - a validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.